Introduction
============

Dyskeratosis congenita (DC) is an inherited syndrome that was first described by Zinsser in 1910, and further characterized by Engman (1926) and Cole et al. in 1930 \[[@B1]\]. It is estimated to occur in 1 in 1 million people, with death occurring at a median age of 16 \[[@B1]\]. It typically presents with a triad of mucocutaneous abnormalities consisting of reticulated skin hyperpigmentation, nail dystrophy (both occurring in almost 100% of cases), and mucosal leukoplakia (80% of cases) \[[@B1]\]. Other features occur with lower frequencies and involve virtually every organ system (Table [1](#T1){ref-type="table"}) \[[@B1]\]-\[[@B3]\]. Although rare (approximately one case per million individuals) \[[@B4]\], DC is a serious and usually fatal condition. The main causes of death are bone marrow failure/immunodeficiency (\~60-70%), pulmonary complications (\~10-15%), and malignancy (\~5-10%) \[[@B2]\].

###### 

Clinical abnormalities reported, so far, in association with dyskeratosis congenita

  Organ system                Defect or abnormality
  --------------------------- ------------------------------------------------
  Skin                        Abnormal skin pigmentation
                              Chronic dermal ulcer
                              Hyperhidrosis
  Nail                        Nail dystrophy
  Oral cavity                 Extensive dental caries
                              Dental loss
                              Leukoplakia
                              Squamous carcinoma of the mouth
  Hair                        Premature hair
                              Alopecia
                              Grey hair
                              Sparse eyelashes
  Lungs                       Asthma
                              Pulmonary fibrosis
                              Hepatopulmonary syndrome
                              Pulmonary microvascular abnormalities
                              Bronchiectasis
                              Fibrocystic dysplasia
                              *Pneumocystis jiroveci* pneumonia
                              Chronic pneumonitis
  Gastrointestinal            Esophageal stricture
                              Peptic ulceration
                              Enteropathy
                              Liver disease (cirrhosis, portal hypertension)
                              Gastrointestinal adenocarcinoma
  Genitourinary               Hypogonadism
                              Undescended testes
                              Urethral stricture
                              Phimosis
  Central Nervous System      Learning difficulties
                              Developmental delay
                              Mental retardation
                              Ataxia
                              Cerebellar hypoplasia
                              Cerebellar malformation
                              Microcephaly
                              Peripheral neuropathy
  Hematologic                 Bone marrow failure
                              Hodgkin\'s lymphoma
  Skeletal                    Osteoporosis
                              Aseptic necrosis
                              Scoliosis
                              Short stature
  Ophthalmic                  Epiphora
                              Chronic keratoconjunctivitis
  Gynecologic and Obstetric   Intrauterine growth retardation
                              Vaginal squamous cell carcinoma
                              Cervical squamous cell carcinoma
  ENT                         Deafness
                              Laryngeal carcinoma
                              Nasopharyngeal carcinoma

Pulmonary involvement occurs in as many as 20% of DC patients \[[@B5]\]. A wide spectrum of respiratory manifestations has been reported, including asthma, pulmonary fibrosis, hepatopulmonary syndrome, pulmonary microvasculature abnormalities, bronchiectasis, fibrocystic dysplasia, *Pneumocystis jiroveci* pneumonia and chronic pneumonitis \[[@B6]\]-\[[@B9]\]. In this article, we describe an unusual case of fatal bilateral spontaneous pneumothoraces in a woman with DC.

Case presentation
=================

A 31-year-old Lebanese woman presented to our medical centre with acute onset of shortness of breath and pleuritic chest pain. Her medical history dated back to 20 years before presentation, when she started developing neck and upper chest skin hyperpigmentation along with progressive hair loss. A few years later, she was found to have pancytopenia and bone marrow hypoplasia and was diagnosed with DC. Since that time, she had been receiving blood transfusions regularly in another medical institution. Her family history was remarkable for parental consanguinity and a diagnosis of DC in one sister who died of an unknown DC-associated complication. The review of systems was non-contributory.

Physical examination showed a tall, slender woman with diffuse alopecia, loss of eyebrows and areas of reticulate hyperpigmentation over the neck and upper chest. Patches of leukoplakia were present on the tongue with atrophy of the glossal papillae. She was dyspneic at rest but hemodynamically stable. Hyper-resonance, decreased breath sounds over the left lung and *velcro* crackles were noted on lung examination. In addition, there was atrophy and longitudinal ridging of the nail beds. No digital clubbing was noted. Cardiovascular, abdominal, and neurological examinations were normal.

Chest X-ray revealed a large left pneumothorax estimated at 35% and reticulonodular infiltrates involving both lung fields (Figure [1](#F1){ref-type="fig"}). An X-ray done 1 year earlier showed bilateral peripheral patchy hyperdensities associated with pulmonary hyperinflation and areas of honeycombing in the right lower lobe consistent with interstitial fibrosis (Figure [2](#F2){ref-type="fig"}).

![**Chest X-ray film taken on the first admission to our institution showing large left pneumothorax estimated at 35% and reticulonodular infiltrates involving both lung fields**.](1752-1947-0003-0000006622-1){#F1}

![**Chest X-ray film taken 1 year before the patient\'s first admission to our institution, showing patchy areas of increased density in the periphery of both lung fields, hyperinflation of the lungs and areas of honeycombing in the right lower lobe consistent with interstitial fibrosis**.](1752-1947-0003-0000006622-2){#F2}

A chest tube was inserted into the left pleural space and placed under negative pressure. Five days later, the left lung had not expanded despite the absence of a bronchopleural leak. The patient continued to be hemodynamically stable. Her shortness of breath and pain improved slightly. The decision was then made to remove the chest tube and discharge the patient home.

Three months later, she presented again with sudden onset of chest discomfort. An X-ray of the chest at that time showed a right-sided pneumothorax estimated at 50%, with persistence of the old left pneumothorax. A chest tube was inserted in the right pleural space (Figure [3](#F3){ref-type="fig"}). She was later intubated and placed on Assist-Control low-tidal volume mechanical ventilation for worsening hypoxic respiratory failure. Her initial FiO~2~ requirement was 80% for 3 days, and then progressively decreased to 60%. The positive end-expiratory pressure (PEEP) was maintained at 5mmHg. Over a 3-week period, although the chest tubes were in place and no bronchopleural air leakage was noted, there was no significant improvement in either of the bilateral pneumothoraces. The PaO~2~/FiO~2~ ratio was constantly rising, reaching around 360 a month into the ICU admission, when the patient passed away due to intractable hypoxic respiratory failure. The poor lung re-expansion was documented bilaterally by serial X-rays, and there was no evidence of ventilator-associated pneumonia or any additional comorbidity.

![**Chest X-ray film taken 3 months after the patient\'s first admission to our institution, showing a right-sided pneumothorax, estimated at 50%, with persistence of the left pneumothorax; right chest tube in place**.](1752-1947-0003-0000006622-3){#F3}

Discussion
==========

DC is a multisystem genodermatosis where distinctive mucocutaneous lesions occur in combination with bone marrow failure, pulmonary disease and an increased risk of malignancy \[[@B1]\]. The mode of inheritance is an X-linked recessive pattern in the majority of cases \[[@B10]\]. DC continues to stimulate clinical and research interest because, although rare, it is devastating for the patient and his/her family \[[@B11]\].

Our patient presented with several typical features of DC: reticulate pigmentation of the neck and upper chest with areas of spared skin (confetti spots), dystrophic nails, diffuse alopecia, together with the characteristic bone marrow failure and interstitial fibrosis. The course of her disease was remarkable for the development of spontaneous bilateral pneumothoraces leading to intractable hypoxic respiratory failure and death despite chest tube insertion, application of negative pressure and use of mechanical ventilation. The sister\'s DC diagnosis and the parental consanguinity suggest an autosomal recessive rather than the more usual X-linked inheritance mode \[[@B10]\]. Subsequently, three other members of the same family were diagnosed with DC, making autosomal recessive inheritance even more likely. Unfortunately, genetic testing was not available at that time to confirm the specific genotype or inheritance mode.

Pulmonary disease in patients with DC has rarely been reported and poorly documented \[[@B7]\]. However, pulmonary involvement may be underestimated because many DC patients die at an early age, before the onset of respiratory symptoms. In addition, DC patients may present with primary respiratory complaints and the condition goes unrecognized because of minor dermatologic manifestations \[[@B10]\].

A 1973 review of the literature identified fibrotic lung changes in only 2 of 35 reported patients \[[@B12]\]. The DC registry established at the Hammersmith Hospital (London) reported in year 2000 that 20.3% of 148 patients from 92 families exhibited reduced diffusion capacity and/or restrictive defects on pulmonary function testing \[[@B2]\]. So far, a total of eight patients have been reported with biopsy-proven pulmonary fibrosis \[[@B13]\]. Other reported pulmonary manifestations of DC include asthma, hepatopulmonary syndrome, pulmonary microvasculature abnormalities, bronchiectasis, fibrocystic dysplasia, *Pneumocystis jiroveci* pneumonia and chronic pneumonitis \[[@B6]\]-\[[@B9]\].

Secondary spontaneous pneumothorax is a condition mainly seen in patients with asthma, chronic obstructive pulmonary disease (COPD), infections (including abscess, tuberculosis, *Pneumocystis jiroveci* pneumonia) and malignancies. It is less commonly reported in patients with interstitial lung disease as part of specific syndromes such as lymphangioleiomyomatosis and histiocytosis X. It has rarely been reported in patients with DC. To the best of our knowledge, the only report of a pneumothorax complicating DC was that by Verra *et al.*, in 1992 \[[@B7]\]. The patient in question was admitted for acute respiratory failure precipitated by a unilateral, left-sided pneumothorax and passed away 10 days later despite chest tube insertion and oxygen therapy. Similarly, our patient developed fatal bilateral pneumothoraces refractory to chest tube insertion, application of negative pressure and use of mechanical ventilation. In both cases, a pneumothorax occurring in the setting of DC was fatal.

The pathophysiology of the different DC manifestations remains incompletely characterized despite significant advances in our understanding of the genetics and biology of this disease during the last decade \[[@B1]\]. It is currently believed that DC arises principally from defective telomere maintenance, resulting in chromosomal shortening and gene loss during cell replication ultimately leading to cell apoptosis, particularly in highly proliferative tissues such as the hematologic and dermatologic systems \[[@B11]\]. Utz *et al.* speculated that pulmonary fibrosis in this setting is secondary to an abnormal fibroblast function \[[@B13]\]. Once established, this pulmonary fibrosis may lead to alveolar wall degeneration, cyst formation and rupture, and therefore to a pneumothorax. Furthermore, since DC has been shown to be associated with pulmonary microvascular abnormalities \[[@B7]\], it is also possible that pneumothoraces are the result of pulmonary infarctions. The absence of lung re-expansion after chest tube insertion observed in the course of our patient\'s illness can be multifactorial: for example, extensive fibrosis could have permanently deformed the lung and prevented significant re-expansion, or infarction involving a significant part of the lung parenchyma could have delayed healing.

Traditionally, treatment options for bone marrow failure in patients with DC include anabolic steroids (for example, oxymetholone), granulocyte macrophage colony-stimulating factor, granulocyte colony-stimulating factor and erythropoietin \[[@B14]\]. However, this kind of therapy has been associated with only a transient increase in blood counts and serious adverse effects \[[@B15]\]. Hematopoietic stem cell transplantation has a limited success rate because of a high prevalence of fatal pulmonary complications, mainly in patients with significant pre-existing pulmonary involvement. No data are available, thus far, regarding the management of pulmonary manifestations in DC patients. The emerging insights into the molecular biology of this disease will hopefully provide new opportunities for preventive and therapeutic interventions.

Conclusion
==========

In summary, we describe the case of a patient with typical DC symptoms who presented with bilateral pneumothoraces, refractory to existing medical treatment. This is the second reported pneumothorax occurrence in the context of DC. In both reports, the outcome was fatal despite maximal medical therapy. Therefore, a high degree of suspicion of this and other potential pulmonary complications in patients with DC, and surveillance pulmonary function testing and chest imaging are warranted for early effective interventional strategies.
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